Mechanism-based inactivation of CYP3A by HIV protease inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 2, 2005, Pages 583-591

  Ernest II, C Steven ^a   Hall, Stephen D ^a   Jones, David R ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CYTOCHROME P450 3A; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ALDEHYDES; ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; IRON; KINETICS; MICROBIAL SENSITIVITY TESTS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; REACTIVE OXYGEN SPECIES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 13244299150     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.075416     Document Type: Article

References (54)

1. Alsenz J, Steffen H, and Alex R (1998) Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in caco-2 cell monolayers. [published erratum appears in Pharmacol Res 15:958]. Pharmacol Res 15:423-428.
2. Bensoussan C, Delaforge M, and Mansuy D (1995) Particular ability of cytochromes P450 3A to from inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 49:591-602.
3. Chiba M, Hensleigh M, and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem Pharmacol 53:1187-1195.
4. Correia MA (1991) Cytochrome P450 turnover. Methods Enzymol 206:315-325.
5. de Maat MMR, Ekhart GC, Huitema ADR, Koks CHW, Mulder JW, and Beijen JH (2003) Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 42:223-282.
6. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SN, and Surber BW (1997) Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs and humans. Drug Metab Dispos 25:489-501.
7. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
8. Eagling VA, Wiltshire H, Whitcombe IWA, and Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17.
9. Fichtenbaum CJ and Gerber JG (2002) Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41:1195-1211.
10. Fichtenbaum CJ, Gerber JG, Rosenkranz YS, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, and Aweeka F: NIAID AIDS Clinical Trials Group (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16:569-577.
11. Franklin MR (1977) Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacol Ther 2:227-245.
12. Gibbs MA, Kunze KL, Howald WN, and Thummel KE (1999) Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27:596-599.
13. Gorski JC, Jones DR, Wrighton SA, and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes: contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
14. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000a) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136.
15. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, and Shader RI (2000b) Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 67:335-341.
16. Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, et al. (2003) Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 43:414-422.
17. Guitton J, Buronfosse T, Desage M, Lepape A, Brazier J, and Beaune P (1997) Possible involvement of multiple cytochrotne P450s in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 53:1613-1619.
18. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, et al. (2002) Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. J Am Med Assoc 288:169-180.
19. Hsu A, Granneman GR, and Bertz RJ (1998) Ritonavir: clinical pharmacokinetics and interactions with other ant-HIV agents. Clin Pharmacokinet 35:275-291.
20. Hsyu P, Schultz-Smith MD, Lillibridge JH, Lewis RH, and Kerr BM (2001) Pharmacokinetic interactions between nelfinavir and 3-hydrocy-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 45:3445-3450.
21. Jauch R, Kopitar Z, Prox A, and Zimmer A (1976) Pharmacokinetics and metabolism of trazodone in man. Arzeneim-Forsch 26:2084-2089.
22. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116-1999.
23. Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K, and Sugiyama Y (2000) Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil. Drug Metab Dispos 28:467-474.
24. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
25. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
26. Kumar GN, Jayanti V, Lee RD, Whittern DN, Uchic J, Thomas S, Johnson P, Grabowski B, Sham H, Betebenner D, et al. (1999) In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos 27:86-91.
27. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, and Lee CA (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609-616.
28. Lin JH, Chiba M, Chen IW, Vastag KJ, Nishime JA, Dorsey BD, Michelson SR, and McDaniel SL (1995) Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J Pharmacol Exp Ther 274:264-269.
29. Lowery OH, Rosebrough HJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin-phenol reagents. J Biol Chem 193:265-275.
30. Malhotra S, Schmiedlin-Ren P, Paine MF, Criss AB, and Watkins P (2001) The furocoumarin 6′,7′-dihydroxybergamottin (DHB) accelerates CYP3A4 degradation via the ubiquitin-proteasomal pathway. Drug Metab Rev 33:97.
31. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
32. Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, Mulcahy F, and Back DJ (1999) Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 13:F101-F107.
33. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, and Buss N (2000) Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 50:99-107.
34. Nilsen OG and Dale O (1992) Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol Toxicol 71:150-153.
35. Olkkola KT, Palkama VJ, and Neuvonen PJ (1999) Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 91:681-685.
36. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2379-2385.
37. Palkama VJ, Ahonen J, Neuvonen PJ, and Olkkola KT (1999) Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 66:33-39.
38. Pershing LK and Franklin MR (1982) Cytochrome P-450 metabolic- intermediate complex formation and induction by macrolide antibiotics: a new class of agents. Xenobiotica 12:687-699.
39. Rodrigues AD, Winchell GA, and Dobrinska MR (2001) Use of in vitro metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 41:368-373.
40. Schuetz EG, Beck WT, and Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
41. Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, John Wiley & Sons, Inc., New York.
42. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
43. Singh R, Chang SY, and Taylor LCE (1996) In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9. Rapid Commun Mass Spectrom 10:1019-1026.
44. Srinivas RV, Middlemas D, Flynn P, and Fridland A (1998) Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42:3157-3162.
45. Tateishi T, Wood AJJ, Guengerich FP, and Wood M (1995) Biotransformation of tritiated fentanyl in humans liver microsomes: monitoring metabolism using phenylacetic acid and 2-phenylethanol. Biochem Pharmacol 50:1921-1924.
46. Thummel KE and Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed (Hardman JG and Limbird LE eds) pp 1917-2023, McGraw-Hill Book Company, New York.
47. Unadkat JD and Wang Y (2000) Antivirals, in Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD, and Eichelbaum M eds) pp 421-433, Lippincott Williams & Wilkins, Philadelphia.
48. Wang Y, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:1-8.
49. Warrington JS, Shader RI, von Moltke LL, and Greenblatt DJ (2000) In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28:392-397.
50. Washington CB, Duran GE, Man MC, Sikic BI, and Blaschke TF (1998) Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retroviral 19:203-209.
51. Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, and Blaschke TF: AIDS Clinical Trials Group Protocol 378 (ACTG 378) Study Team (2003) Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther 73:406-416.
52. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. (2002) Antiretroviral treatment for adult HIV infections in 2002. Updated recommendation of the International AIDS Society-USA Panel. J Am Med Assoc 288:222-235.
53. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, and Webber S (2001) Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma and antiviral activities. Antimicrob Agents Chemother 45:1086-1093.
54. Zhao XJ, Jones DR, Wang YH, Grimm SW, and Hall SD (2002) Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32:863-878.